Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation

Yoshinobu Aisa, Takehiko Mori, Tomonori Nakazato, Takayuki Shimizu, Rie Yamazaki, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Eosinophilia is observed in a variety of disorders including acute and chronic graft-versus-host disease (GVHD). The clinical records of 237 patients who underwent allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed. Eosinophilia, defined as a relative eosinophil count >4% within the first 100 days, was observed in 135 patients (57%). The incidence of grades II-IV acute GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (68% vs. 43%; P < 0.001). The incidence of chronic GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (73% vs. 56%; P = 0.011). Relapse rate was similar between patients with and without eosinophilia (33% vs. 27%; P = 0.438). The probability of nonrelapse mortality was 10% in patients with eosinophilia, which was significantly lower than that in patients without eosinophilia (31%; P < 0.001), and the overall survival (OS) at 3 years was 67% in patients with eosinophilia, which was significantly higher than that in patients without eosinophilia (51%; P = 0.003). Multivariate analysis identified older age, high-risk disease, acute GVHD, sex disparity between patient and donor, and the absence of eosinophilia as significant factors for reduced OS. These data lead us to conclude that eosinophilia after allo-SCT may serve as a favorable prognostic marker.

Original languageEnglish
Pages (from-to)761-770
Number of pages10
JournalTransplant International
Volume20
Issue number9
DOIs
Publication statusPublished - 2007 Sep

Fingerprint

Eosinophilia
Stem Cell Transplantation
Graft vs Host Disease
Survival
Incidence
Acute Disease
Eosinophils
Multivariate Analysis
Tissue Donors

Keywords

  • Allogeneic stem cell transplantation
  • Eosinophilia
  • Graft-versus-host disease
  • Relapse
  • Survival

ASJC Scopus subject areas

  • Transplantation

Cite this

Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. / Aisa, Yoshinobu; Mori, Takehiko; Nakazato, Tomonori; Shimizu, Takayuki; Yamazaki, Rie; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Transplant International, Vol. 20, No. 9, 09.2007, p. 761-770.

Research output: Contribution to journalArticle

@article{4c81139b6cf14b12b1ace7f88abe327c,
title = "Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation",
abstract = "Eosinophilia is observed in a variety of disorders including acute and chronic graft-versus-host disease (GVHD). The clinical records of 237 patients who underwent allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed. Eosinophilia, defined as a relative eosinophil count >4{\%} within the first 100 days, was observed in 135 patients (57{\%}). The incidence of grades II-IV acute GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (68{\%} vs. 43{\%}; P < 0.001). The incidence of chronic GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (73{\%} vs. 56{\%}; P = 0.011). Relapse rate was similar between patients with and without eosinophilia (33{\%} vs. 27{\%}; P = 0.438). The probability of nonrelapse mortality was 10{\%} in patients with eosinophilia, which was significantly lower than that in patients without eosinophilia (31{\%}; P < 0.001), and the overall survival (OS) at 3 years was 67{\%} in patients with eosinophilia, which was significantly higher than that in patients without eosinophilia (51{\%}; P = 0.003). Multivariate analysis identified older age, high-risk disease, acute GVHD, sex disparity between patient and donor, and the absence of eosinophilia as significant factors for reduced OS. These data lead us to conclude that eosinophilia after allo-SCT may serve as a favorable prognostic marker.",
keywords = "Allogeneic stem cell transplantation, Eosinophilia, Graft-versus-host disease, Relapse, Survival",
author = "Yoshinobu Aisa and Takehiko Mori and Tomonori Nakazato and Takayuki Shimizu and Rie Yamazaki and Yasuo Ikeda and Shinichiro Okamoto",
year = "2007",
month = "9",
doi = "10.1111/j.1432-2277.2007.00509.x",
language = "English",
volume = "20",
pages = "761--770",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation

AU - Aisa, Yoshinobu

AU - Mori, Takehiko

AU - Nakazato, Tomonori

AU - Shimizu, Takayuki

AU - Yamazaki, Rie

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2007/9

Y1 - 2007/9

N2 - Eosinophilia is observed in a variety of disorders including acute and chronic graft-versus-host disease (GVHD). The clinical records of 237 patients who underwent allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed. Eosinophilia, defined as a relative eosinophil count >4% within the first 100 days, was observed in 135 patients (57%). The incidence of grades II-IV acute GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (68% vs. 43%; P < 0.001). The incidence of chronic GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (73% vs. 56%; P = 0.011). Relapse rate was similar between patients with and without eosinophilia (33% vs. 27%; P = 0.438). The probability of nonrelapse mortality was 10% in patients with eosinophilia, which was significantly lower than that in patients without eosinophilia (31%; P < 0.001), and the overall survival (OS) at 3 years was 67% in patients with eosinophilia, which was significantly higher than that in patients without eosinophilia (51%; P = 0.003). Multivariate analysis identified older age, high-risk disease, acute GVHD, sex disparity between patient and donor, and the absence of eosinophilia as significant factors for reduced OS. These data lead us to conclude that eosinophilia after allo-SCT may serve as a favorable prognostic marker.

AB - Eosinophilia is observed in a variety of disorders including acute and chronic graft-versus-host disease (GVHD). The clinical records of 237 patients who underwent allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed. Eosinophilia, defined as a relative eosinophil count >4% within the first 100 days, was observed in 135 patients (57%). The incidence of grades II-IV acute GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (68% vs. 43%; P < 0.001). The incidence of chronic GVHD was significantly higher in patients without eosinophilia than in those with eosinophilia (73% vs. 56%; P = 0.011). Relapse rate was similar between patients with and without eosinophilia (33% vs. 27%; P = 0.438). The probability of nonrelapse mortality was 10% in patients with eosinophilia, which was significantly lower than that in patients without eosinophilia (31%; P < 0.001), and the overall survival (OS) at 3 years was 67% in patients with eosinophilia, which was significantly higher than that in patients without eosinophilia (51%; P = 0.003). Multivariate analysis identified older age, high-risk disease, acute GVHD, sex disparity between patient and donor, and the absence of eosinophilia as significant factors for reduced OS. These data lead us to conclude that eosinophilia after allo-SCT may serve as a favorable prognostic marker.

KW - Allogeneic stem cell transplantation

KW - Eosinophilia

KW - Graft-versus-host disease

KW - Relapse

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34547693444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547693444&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2007.00509.x

DO - 10.1111/j.1432-2277.2007.00509.x

M3 - Article

C2 - 17578455

AN - SCOPUS:34547693444

VL - 20

SP - 761

EP - 770

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 9

ER -